Testicular cancer, version 2.2015 Journal Article
| Authors: | Motzer, R. J.; Jonasch, E.; Agarwal, N.; Beard, C.; Bhayani, S.; Bolger, G. B.; Chang, S. S.; Choueiri, T. K.; Costello, B. A.; Derweesh, I. H.; Gupta, S.; Hancock, S. L.; Kim, J. J.; Kuzel, T. M.; Lam, E. T.; Lau, C.; Levine, E. G.; Lin, D. W.; Michaelson, M. D.; Olencki, T.; Pili, R.; Plimack, E. R.; Rampersaud, E. N.; Redman, B. G.; Ryan, C. J.; Sheinfeld, J.; Shuch, B.; Sircar, K.; Somer, B.; Wilder, R. B.; Dwyer, M.; Kumar, R. |
| Article Title: | Testicular cancer, version 2.2015 |
| Abstract: | Germ cell tumors (GCTs) account for 95% of testicular cancers. Testicular GCTs constitute the most common solid tumor in men between the ages of 20 and 34 years, and the incidence of testicular GCTs has been increasing in the past 2 decades. Testicular GCTs are classified into 2 broad groups - pure seminoma and nonseminoma - which are treated differently. Pure seminomas, unlike nonseminomas, are more likely to be localized to the testis at presentation. Nonseminoma is the more clinically aggressive tumor associated with elevated serum concentrations of alphafetoprotein (AFP). The diagnosis of a seminoma is restricted to pure seminoma histology and a normal serum concentration of AFP. When both seminoma and elements of a nonseminoma are present, management follows that for a nonseminoma. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Testicular Cancer outline the diagnosis, workup, risk assessment, treatment, and follow-up schedules for patients with both pure seminoma and nonseminoma. © JNCCN - Journal of the National Comprehensive Cancer Network. |
| Keywords: | cancer chemotherapy; cancer surgery; overall survival; clinical feature; review; advanced cancer; cancer risk; cancer adjuvant therapy; cancer radiotherapy; cancer staging; positron emission tomography; follow up; cancer diagnosis; cancer incidence; lymph node dissection; cancer palliative therapy; protein blood level; computer assisted tomography; image analysis; practice guideline; cancer therapy; risk factor; risk assessment; blood analysis; cancer epidemiology; orchiectomy; testis cancer; germ cell tumor; seminoma; induction chemotherapy; alpha fetoprotein; recurrence free survival; disease surveillance; managed care; clinical trial (topic); intermediate risk patient; phase 2 clinical trial (topic); meta analysis (topic); testis nonseminoma cancer; clinical classification; human; male; patient risk |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 13 |
| Issue: | 6 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2015-06-01 |
| Start Page: | 772 |
| End Page: | 799 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 26085393 |
| DOI/URL: | |
| Notes: | Export Date: 3 August 2015 -- Source: Scopus |
Citation Impact
Related MSK Work